Progress of local drug therapy in tracheobronchial tuberculosis

doi:10.3969/j.issn.1000-6621.2021.10.021

Abstract

Abstract:

The tracheobronchial tuberculosis (TBTB) lacks typical and clinical presentation, and misdiagnosis is common. In recent years,with the development of bronchoscopy and bronchial intervention technology, the detection rate of TBTB has increased significantly. Besides systemic antituberculosis therapy, there are more and more treatment methods, such as local drug therapy in airway, balloon dilatation, cryotherapy, thermal ablation and stent placement. However, there is no uniform and normative guideline at present. In order to provide a rapid and effective combination scheme for the local treatment of TBTB, the author summarizes the local antituberculosis treatment of TBTB, the common methods to prevent airway stenosis and the local medication strategies of multidrug-resistant TBTB, as well as the research progress of new local medication methods and new inhalation drugs.

Key words: Tuberculosis, Trachea, Bronchi, Bronchoscopes, Administration, topical

LI Ying, CAO Yi-rui, TAO Hong-zhu, YUAN Hao, YU Yu-juan. Progress of local drug therapy in tracheobronchial tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1096-1101. doi: 10.3969/j.issn.1000-6621.2021.10.021

References 62

[1]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行). 中华结核和呼吸杂志, 2012, 35(8): 581-587. doi: 10.3760/cma.j.issn.1001-0939.2012.08.007. doi: 10.3760/cma.j.issn.1001-0939.2012.08.007
[2]	Shahzad T, Irfan M. Endobronchial tuberculosis-a review. J Thorac Dis, 2016, 8(12): 3797-3802. doi: 10.21037/jtd.2016.12.73. doi: 10.21037/jtd.2016.12.73 pmid: 28149579
[3]	金发光. 支气管结核介入的诊治方案. 中华肺部疾病杂志(电子版), 2016, 9(1): 1-4. doi: 10.3877/cma.j.issn.1674-6902.2016.01.001. doi: 10.3877/cma.j.issn.1674-6902.2016.01.001
[4]	肖芃, 赵自洁, 刘伟光. 纤维支气管镜在支气管结核治疗中的应用. 中华结核和呼吸杂志, 2001, 24(2): 116. doi: 10.3760/j:issn:1001-0939.2001.02.019. doi: 10.3760/j:issn:1001-0939.2001.02.019
[5]	高同军, 李芳, 陈希琛. 支气管结核248例临床分析. 中国防痨杂志, 2002, 24(1): 29-31. doi: 10.3969/j.issn.1000-6621.2002.01.012. doi: 10.3969/j.issn.1000-6621.2002.01.012
[6]	陆兰英, 靖秋生, 王卫华. 经纤维支气管镜注药联合雾化吸入治疗支气管结核的疗效观察. 中国防痨杂志, 2010, 32(2): 104-107.
[7]	孙纪英, 李曦, 邓长国. 布地奈德联合异烟肼雾化吸入辅助治疗初治肺结核合并支气管结核临床观察. 四川医学, 2016, 37(1): 44-46. doi: 10.16252/j.cnki.issn1004-0501-2016.01.011. doi: 10.16252/j.cnki.issn1004-0501-2016.01.011
[8]	高云玲, 陈晓红, 陈素卿. 两种雾化吸入方案对气管支气管结核的近期疗效及不良反应观察. 中国防痨杂志, 2017, 39(2): 163-168. doi: 10.3969/j.issn.1000-6621.2017.02.012. doi: 10.3969/j.issn.1000-6621.2017.02.012
[9]	Guo X, Wang C, Wang X, et al. Characteristics and risk factor analysis of 410 cases of tracheobronchial tuberculosis. Exp Ther Med, 2014, 8(3): 781-784. doi: 10.3892/etm.2014.1804. doi: 10.3892/etm.2014.1804 URL
[10]	Rikimaru T, Koga T, Sueyasu Y, et al. Treatment of ulcerative endobronchial tuberculosis and bronchial stenosis with aerosolized streptomycin and steroids. Int J Tuberc Lung Dis, 2001, 5(8): 769-774. doi: 10.1258/0956462011923534. doi: 10.1258/0956462011923534 pmid: 11495269
[11]	王建云, 白少丽, 李宗煜, 等. 卷曲霉素雾化吸入治疗支气管内膜结核的疗效观察//中华医学会结核病学分会. 2019年全国结核病学术大会论文汇编,苏州,2019. 北京:中华医学会结核病学分会, 2019: 115. doi: 10.26914/c.cnkihy.2019.023575. doi: 10.26914/c.cnkihy.2019.023575
[12]	方育霞, 李光明, 杨蓉美, 等. 支气管镜冷冻及注药联合雾化治疗溃疡坏死型支气管结核. 第三军医大学学报, 2015, 37(20): 2106-2108. doi: 10.16016/j.1000-5404.201505127. doi: 10.16016/j.1000-5404.201505127
[13]	李艳静, 常占平, 刘恩利, 等. 支气管镜下注药联合雾化吸入治疗支气管结核的疗效观察. 中国临床研究, 2017, 30(1): 58-60. doi: 10.13429/j.cnki.cjcr.2017.01.016. doi: 10.13429/j.cnki.cjcr.2017.01.016
[14]	周仲志, 陶艳红, 陈中红. 纤维支气管镜下局部注药治疗气管支气管结核的疗效观察. 中国防痨杂志, 2004, 26(3): 139-141. doi: 10.3969/j.issn.1000-6621.2004.03.004. doi: 10.3969/j.issn.1000-6621.2004.03.004
[15]	陶满意, 杜凤华, 杨淇, 等. 经支气管镜介入治疗气管支气管结核的临床疗效分析. 吉林医学, 2016, 37(1): 65-68. doi: 10.3969/j.issn.1004-0412.2016.01.027. doi: 10.3969/j.issn.1004-0412.2016.01.027
[16]	孙明华. 局部给药治疗支气管结核的临床疗效. 临床肺科杂志, 2017, 22(9): 1716-1718, 1721. doi: 10.3969/j.issn.1009-6663.2017.09.049. doi: 10.3969/j.issn.1009-6663.2017.09.049
[17]	叶涛生, 张培泽, 曾旋, 等. 经支气管镜治疗淋巴结瘘型支气管结核的效果分析. 新发传染病电子杂志, 2018, 3(4): 202-205. doi: 10.3877/j.issn.2096-2738.2018.04.003. doi: 10.3877/j.issn.2096-2738.2018.04.003
[18]	申静, 纪俊雨, 郝蒙, 等. 纤支镜气管内注入异烟肼联合利福平治疗支气管结核临床观察. 中国药业, 2020, 29(6): 125-127. doi: 10.3969/j.issn.1006-4931.2020.06.037. doi: 10.3969/j.issn.1006-4931.2020.06.037
[19]	吕志芳, 潘青. 经纤支镜下局部注药治疗气管支气管结核的疗程研究. 中华全科医学, 2018, 16(8): 1283-1285. doi: 10.16766/j.cnki.issn.1674-4152.000352. doi: 10.16766/j.cnki.issn.1674-4152.000352
[20]	黄信刚, 郑东元, 周淮英, 等. 支气管结核纤维支气管镜下局部清理、注药与联合微波治疗的疗效比较. 中南大学学报, 2005, 30(1): 115-116. doi: 10.3321/j.issn:1672-7347.2005.01.029. doi: 10.3321/j.issn:1672-7347.2005.01.029
[21]	曾迎春, 杨银妹, 周松林. 康复新液与标准结核化疗药物联用对气管支气管结核局部给药的疗效评价. 抗感染药学, 2016, 13(4): 865-867. doi: 10.13493/j.issn.1672-7878.2016.04-052. doi: 10.13493/j.issn.1672-7878.2016.04-052
[22]	李庆伟, 孔祥臣, 刘莹, 等. 支气管镜局部注射化疗在支气管结核患者治疗中的应用. 临床肺科杂志, 2018, 23(5): 929-933. doi: 10.3969/j.issn.1009-6663.2018.05.042. doi: 10.3969/j.issn.1009-6663.2018.05.042
[23]	耿书军, 刘建玲, 高官聚, 等. 经支气管镜局部注射辅助治疗耐多药肺结核的疗效及对患者免疫功能的影响. 中国内镜杂志, 2015, 21(3): 243-245.
[24]	李力. 支气管镜冷冻及注药联合治疗耐多药肺结核的痰菌转阴情况及免疫功能评估. 海南医学院学报, 2016, 22(15): 1663-1665,1669. doi: 10.13210/j.cnki.jhmu.20160614.007. doi: 10.13210/j.cnki.jhmu.20160614.007
[25]	王云南, 刘伟光, 张宇青, 等. 雾化吸入抗结核药对支气管内膜结核患者疗效的影响. 临床荟萃, 2001, 16(3): 99-100. doi: 10.3969/j.issn.1004-583X.2001.03.001. doi: 10.3969/j.issn.1004-583X.2001.03.001
[26]	Miki K, Yokota S, Hiraga T, et al. Effectiveness of isoniazid inhalation in patients with endobronchial tuberculosis. Nihon Kokyuki Gakkai Zasshi, 1999, 37(1): 31-35. pmid: 10087873
[27]	丁卫民, 傅瑜. 关于“气管支气管结核诊断和治疗指南(试行)”的几点补充说明. 中华结核和呼吸杂志, 2013, 36(2): 159-160. doi: 10.3760/cma.j.issn.1001-0939.2013.02.030. doi: 10.3760/cma.j.issn.1001-0939.2013.02.030
[28]	彭渝, 胡成平, 杨华平, 等. 1221例支气管结核的支气管镜结果分析. 中国呼吸与危重监护杂志, 2015, 14(2): 182-185. doi: 10.7507/1671-6205.2015046. doi: 10.7507/1671-6205.2015046
[29]	Chung HS, Lee JH. Bronchoscopic assessment of the evolution of endobronchial tuberculosis. Chest, 2000, 117(2): 385-392. doi: 10.1378/chest.117.2.385. doi: 10.1378/chest.117.2.385 pmid: 10669679
[30]	Sahin F, Yildiz P. Characteristics of endobronchial tuberculosis patients with negative sputum acid-fast bacillus. J Thorac Dis, 2013, 5(6): 764-770. doi: 10.3978/j.issn.2072-1439.2013.12.15. doi: 10.3978/j.issn.2072-1439.2013.12.15
[31]	Yaguchi D, Ichikawa M, Shizu M, et al. Bronchoscopic local steroid spray to prevent bronchial tuberculosis-induced cicatricial bronchial stenosis: A case series. Medicine (Baltimore), 2018, 97(28): e11464. doi: 10.1097/MD.0000000000011464. doi: 10.1097/MD.0000000000011464 URL
[32]	蔡向敬, 侯玉莲, 段月庭. 支气管镜下球囊高压扩张联合曲安奈德局部注射治疗结核性支气管狭窄的效果观察. 河北医学, 2017, 23(12): 1956-1958. doi: 10.3969/j.issn.1006-6233.2017.12.006. doi: 10.3969/j.issn.1006-6233.2017.12.006
[33]	Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J, 2017, 50(3): 1700037. doi: 10.1183/13993003.00037-2017. doi: 10.1183/13993003.00037-2017 URL
[34]	Huang TM, Kuo KC, Wang YH, et al. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis, 2020, 20(1): 706. doi: 10.1186/s12879-020-05440-6. doi: 10.1186/s12879-020-05440-6 URL
[35]	李培培, 何杰, 李小燕, 等. 丝裂霉素C对良性气道狭窄干预效果的荟萃分析. 国际呼吸杂志, 2020, 40(9): 667-674. doi: 10.3760/cma.j.cn131368-20190922-01319. doi: 10.3760/cma.j.cn131368-20190922-01319
[36]	Cary C, Jhajj M, Cinicola J, et al. A rare case of fibrostenotic endobronchial tuberculosis of trachea. Ann Med Surg (Lond), 2015, 4(4): 479-482. doi: 10.1016/j.amsu.2015.10.007. doi: 10.1016/j.amsu.2015.10.007 URL
[37]	Faisal M, Harun H, Hassan TM, et al. Treatment of multiple-level tracheobronchial stenosis secondary to endobronchial tuberculosis using bronchoscopic balloon dilatation with topical mitomycin-C. BMC Pulm Med, 2016, 16(1): 53. doi: 10.1186/s12890-016-0209-1. doi: 10.1186/s12890-016-0209-1 URL
[38]	Huan NC, Ng KL, Nasaruddin MZ, et al. Topical mitomycin-C as an adjuvant to multimodal endoscopic treatment for tracheobronchial stenosis secondary to endobronchial tuberculosis. Respirol Case Rep, 2021, 9(3): e00711. doi: 10.1002/rcr2.711. doi: 10.1002/rcr2.711
[39]	何芳, 余红, 林洁如, 等. 支气管镜引导下局部无水乙醇注射治疗结核性中央气道瘢痕狭窄的效果. 中国内镜杂志, 2018, 24(10): 6-9. doi: 10.3969/j.issn.1007-1989.2018.10.002. doi: 10.3969/j.issn.1007-1989.2018.10.002
[40]	邝浩斌, 谭守勇, 梁敏青, 等. 耐多药肺结核患者并发气管支气管结核的相关性研究. 中国防痨杂志, 2017, 39(3): 242-246. doi: 10.3969/j.issn.1000-6621.2017.03.007. doi: 10.3969/j.issn.1000-6621.2017.03.007
[41]	Roberts-Witteveen A, Reinten T, Christensen A, et al. Multidrug-resistant tuberculosis in New South Wales,Australia,1999—2010: a case series report. Int J Tuberc Lung Dis, 2015, 19(7): 850-856. doi: 10.5588/ijtld.14.0575. doi: 10.5588/ijtld.14.0575 pmid: 26056113
[42]	高云. 经纤维支气管镜局部注射辅助治疗耐多药肺结核效果评价. 临床输血与检验, 2017, 19(3): 272-275. doi: 10.3969/j.issn.1671-2587.2017.03.017. doi: 10.3969/j.issn.1671-2587.2017.03.017
[43]	高云. 3VHZALP/9VHZL化疗方案联合经纤维支气管镜介入治疗耐多药肺结核并支气管结核的临床疗效. 实用心脑肺血管病杂志, 2016, 24(2): 79-81. doi: 10.3969/j.issn.1008-5971.2016.02.023. doi: 10.3969/j.issn.1008-5971.2016.02.023
[44]	李阳. 经支气管镜灌注治疗联合常规化疗用于耐多药肺结核的疗效评估. 海南医学院学报, 2016, 22(23): 2829-2832. doi: 10.13210/j.cnki.jhmu.20160929.009. doi: 10.13210/j.cnki.jhmu.20160929.009
[45]	孟萍. 支气管镜局部灌洗结合药物灌注对耐多药支气管结核疗效和血清学指标影响. 中国医疗器械信息, 2019, 25(11): 90-91. doi: 10.3969/j.issn.1006-6586.2019.11.043. doi: 10.3969/j.issn.1006-6586.2019.11.043
[46]	王晓平, 郭新美, 徐栗. 经支气管镜治疗淋巴结瘘型支气管结核. 中国内镜杂志, 2015, 21(6): 561-566.
[47]	肖阳宝, 罗林紫, 卢志斌, 等. 超声引导下淋巴结穿刺注射给药联合冷冻治疗破溃期淋巴结瘘型气管支气管结核的价值. 结核与肺部疾病杂志, 2020, 1(3): 149-153. doi: 10.3969/j.issn.2096-8493.2020.02.012. doi: 10.3969/j.issn.2096-8493.2020.02.012
[48]	郭春辉, 张莹, 苏衍举, 等. 不同介入技术治疗炎症浸润型气管支气管结核的随机对照临床研究. 中国防痨杂志, 2019, 41(11): 1211-1216. doi: 10.3969/j.issn.1000-6621.2019.11.012. doi: 10.3969/j.issn.1000-6621.2019.11.012
[49]	唐飞, 吕莉萍. 可弯曲支气管镜下冷热联合消融治疗中央气道淋巴结瘘型支气管结核的价值. 中国防痨杂志, 2019, 41(6): 657-661. doi: 10.3969/j.issn.1000-6621.2019.06.012. doi: 10.3969/j.issn.1000-6621.2019.06.012
[50]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006
[51]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015, 37(5): 421-469. doi: 10.3969/j.issn.1000-6621.2015.05.001. doi: 10.3969/j.issn.1000-6621.2015.05.001
[52]	Momin MAM, Rangnekar B, Sinha S, et al. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies. Pharmaceutics, 2019, 11(10): 502. doi: 10.3390/pharmaceutics11100502. doi: 10.3390/pharmaceutics11100502 URL
[53]	Dharmadhikari AS, Kabadi M, Gerety B, et al. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother, 2013, 57(6): 2613-2619. doi: 10.1128/AAC.02346-12. doi: 10.1128/AAC.02346-12 pmid: 23529740
[54]	Pitner RA, Durham PG, Stewart IE, et al. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy. J Pharm Sci, 2019, 108(10): 3302-3311. doi: 10.1016/j.xphs.2019.05.024. doi: 10.1016/j.xphs.2019.05.024 URL
[55]	Bax HI, de Steenwinkel JE, Ten Kate MT, et al. Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis. J Antimicrob Chemother, 2015, 70(10): 2828-2837. doi: 10.1093/jac/dkv194. doi: 10.1093/jac/dkv194 URL
[56]	Akkerman OW, Grasmeijer F, de Lange WCM, et al. Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. Eur Respir J, 2018, 51(3): 1702490. doi: 10.1183/13993003.02490-2017. doi: 10.1183/13993003.02490-2017 URL
[57]	Mehanna MM, Mohyeldin SM, Elgindy NA. Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery. Int J Nanomedicine, 2019, 14: 9089-9112. doi: 10.2147/IJN.S211182. doi: 10.2147/IJN.S211182 URL
[58]	Berkenfeld K, McConville JT, Lamprecht A. Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy. Expert Opin Drug Deliv, 2020, 17(3): 305-322. doi: 10.1080/17425247.2020.1720644. doi: 10.1080/17425247.2020.1720644 pmid: 32017637
[59]	Santos K, Lukka PB, Grzegorzewicz A, et al. Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular. Front Microbiol, 2018, 9: 1895. doi: 10.3389/fmicb.2018.01895. doi: 10.3389/fmicb.2018.01895 pmid: 30186246
[60]	Stewart IE, Lukka PB, Liu J, et al. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharm Res, 2019, 36(9): 136. doi: 10.1007/s11095-019-2666-8. doi: 10.1007/s11095-019-2666-8 URL
[61]	Rikimaru T, Tanaka Y, Higuchi E, et al. Evaluation of aerosol therapy of streptomycin for tracheobronchial and pulmonary tuberculosis. Kansenshogaku Zasshi, 1992, 66(2): 206-211. doi: 10.11150/kansenshogakuzasshi1970.66.206. doi: 10.11150/kansenshogakuzasshi1970.66.206 pmid: 1402082
[62]	张亮, 周秋云, 陆磊, 等. 雾化吸入阿米卡星在气管支气管结核患者体内的药物分布特点. 临床肺科杂志, 2017, 22(1): 44-47. doi: 10.3969/j.issn.1009-6663.2017.01.013. doi: 10.3969/j.issn.1009-6663.2017.01.013